×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Artificial Heart Market Share

ID: MRFR/HC/6513-HCR
90 Pages
Rahul Gotadki
October 2025

Artificial Heart Market Research Report Information by Type (Heart-Lung Machine, Mechanical Heart, Total Artificial Hearts, Ventricular Assist Devices (VADs)), End User (Hospitals & Clinics, Specialty Centers) and Region (Americas, Europe, Asia-Pacific, Middle East Africa) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Artificial Heart Market Infographic
×
Artificial Heart Market Infographic Full View
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Artificial Heart Market Share Analysis

In the competitive landscape of the Artificial Heart market, market share positioning strategies play a crucial role in determining the success of companies. This involves a strategic approach to carve out a distinct space in the market and gain a competitive edge. When companies are aiming to minimize market share slippage, product differentiation becomes a big issue. This involves the designing of artificial hearts that have a distinctiveness, superseded performance and better result in patients. Companies can create separate one fan’s base due to something special provided and broaden their market share. Cost Leadership is a basic and very relevant market share position strategy. Companies always trying to achieve minimum optimizing manufacturing processes, control production costs and improve operations efficiencies. Price-based competition for an artificial heart’s low price and therefore a price awareness market allows to achieve market dominance. For a competitive market space in the medical field, it is highly critical for healthcare products to meet strict regulatory standards and still rank with high quality. Enhancing market shares positively can be achieved through reputable companies that believe in regulatory compliance and have the reputation of product quality, hence providers for the healthcare professionals and patients’ trust. The adoption of artificial hearts can help educate the market about their advantages and also spread awareness towards emerging technologies; thus eventually reducing percentage growth. Companies spend money on advertising campaigns meant to both educate health care professionals and as well as the public in general, with being able to engender trust and credibility. In the healthcare industry, including artificial heart technology and other similar domains, trends mutate over time. Businesses that earn room for agility and adaptability, which can arise from shifting patient adoption tendencies, or developments with changes in technology, or regulation, create situations where they are able to hold on a majority of the market share during such changes in the market. Providing excellent post-sales support and services is a key aspect of market share positioning. Companies that offer comprehensive training, maintenance services, and responsive customer support contribute to customer satisfaction and loyalty, impacting market share through positive word-of-mouth and repeat business.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What was the valuation in 2030?

The valuation was USD 4.98 billion.

What is the predicted CAGR for the Artificial Heart Market for the forecast period (2022-2030)?

The predicted CAGR would be 14.3%.

What could slow down market growth?

The high cost of the procedure and regulations regarding the process, along with the higher cost of an artificial heart, can slow down the growth.

Which type to lead the market?

The mechanical heart segment has the chance to record a higher CAGR.

Which region would take charge of the artificial heart market?

The Americas market would dominate the global field.

Market Summary

As per MRFR analysis, the Artificial Heart Market Size was estimated at 2581.55 USD Million in 2024. The Artificial Heart industry is projected to grow from 2841.4 USD Million in 2025 to 6635.94 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.92% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Artificial Heart Market is poised for substantial growth driven by technological advancements and increasing demand for heart solutions.

  • North America remains the largest market for artificial hearts, driven by advanced healthcare infrastructure and high patient awareness. The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and a growing aging population. Heart Failure Management is the largest segment, while the Partial Artificial Heart segment is experiencing the fastest growth due to innovative designs and improved patient outcomes. Technological advancements and increased demand for heart solutions are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 2581.55 (USD Million)
2035 Market Size 6635.94 (USD Million)
CAGR (2025 - 2035) 8.92%
Largest Regional Market Share in 2024 North America

Major Players

<p>Abbott Laboratories (US), Medtronic (US), Boston Scientific (US), Cleveland Heart (US), Carmen (DE), SynCardia Systems (US), Jarvik Heart (US), Aortech International (GB), Terumo Corporation (JP)</p>

Market Trends

The Artificial Heart Market is currently experiencing a transformative phase, driven by advancements in technology and increasing demand for innovative cardiac solutions. As healthcare systems evolve, the focus on improving patient outcomes has intensified, leading to a surge in research and development activities. This market is characterized by a growing interest in biocompatible materials and miniaturized devices, which are designed to enhance the quality of life for individuals suffering from severe heart conditions. Furthermore, the integration of artificial intelligence and machine learning into cardiac devices is paving the way for more personalized treatment options, potentially revolutionizing patient care. In addition to technological advancements, the Artificial Heart Market is influenced by demographic shifts and rising awareness regarding heart diseases. An aging population, coupled with lifestyle changes, has resulted in an increased prevalence of cardiovascular disorders. This trend underscores the necessity for effective interventions, thereby propelling the demand for artificial hearts. Moreover, collaborations between medical device manufacturers and healthcare providers are likely to foster innovation and streamline the adoption of these life-saving technologies. As the market continues to evolve, it appears poised for substantial growth, driven by a confluence of factors that prioritize patient-centric solutions and technological integration.

Technological Advancements

The Artificial Heart Market is witnessing rapid technological innovations, particularly in the development of smaller, more efficient devices. These advancements are aimed at improving patient comfort and enhancing device longevity, which may lead to better health outcomes.

Increased Demand for Heart Solutions

There is a growing demand for artificial hearts due to the rising incidence of heart diseases. This trend is likely to drive market expansion as healthcare providers seek effective solutions to address the needs of patients with severe cardiac conditions.

Collaborative Efforts in Research

Collaborations between various stakeholders, including medical device companies and research institutions, are becoming more prevalent. These partnerships may facilitate the development of cutting-edge technologies and promote the integration of artificial hearts into standard treatment protocols.

Artificial Heart Market Market Drivers

Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases globally is a primary driver for the Global Artificial Heart Market Industry. As heart-related ailments continue to escalate, the demand for advanced cardiac solutions, including artificial hearts, is likely to rise. In 2024, the market is projected to reach 5 USD Billion, reflecting the urgent need for innovative treatments. This trend is expected to persist as the World Health Organization indicates that cardiovascular diseases remain the leading cause of death worldwide. Consequently, healthcare systems are compelled to invest in artificial heart technologies to address this growing health crisis.

Market Segment Insights

By Application: Heart Failure Management (Largest) vs. Cardiac Support (Fastest-Growing)

<p>The Artificial Heart Market exhibits a diverse array of applications, with Heart Failure Management holding the largest market share due to the increasing prevalence of heart diseases. This segment plays a critical role in supporting patients who are unable to undergo traditional heart surgeries. Conversely, Cardiac Support has emerged as the fastest-growing segment, fueled by technological advancements and increasing awareness of heart health. As innovative solutions are introduced, a shift in preference towards cardiac support devices is evident, further propelling its growth in the market. Several trends are driving the expansion of the Artificial Heart applications. The rise in cardiac disorders and the aging population create a substantial demand for advanced cardiac interventions. Moreover, research and development in artificial heart technologies, along with favorable reimbursement policies, contribute positively to market dynamics. The emphasis on minimally invasive procedures and improved patient outcomes also indicates a promising trajectory for both heart failure management and cardiac support applications in the coming years.</p>

<p>Heart Failure Management (Dominant) vs. Cardiac Support (Emerging)</p>

<p>Heart Failure Management currently dominates the Artificial Heart Market, primarily due to its critical role in addressing severe heart conditions that require immediate intervention. This segment encompasses a wide range of technologies aimed at improving survival rates and enhancing quality of life for patients with heart failure. On the other hand, Cardiac Support represents an emerging segment that is rapidly gaining ground, particularly with recent innovations focused on enhancing the functionality of existing cardiac systems. With ongoing advancements in device design and materials, Cardiac Support is set to provide vital assistance to patients awaiting heart transplants or those who are ineligible for surgery. The synergy between these two segments underscores the evolving landscape of the Artificial Heart Market, with both playing significant roles in transforming cardiovascular care.</p>

By Type: Total Artificial Heart (Largest) vs. Partial Artificial Heart (Fastest-Growing)

<p>The Artificial Heart Market showcases a complex segmentation with Total Artificial Heart holding the largest market share, driven by its comprehensive solution for patients with end-stage heart failure. On the other hand, the Partial Artificial Heart, which includes various assist devices, is experiencing rapid growth as it gains popularity among patients seeking less invasive options. The distribution of market share among these types reflects the evolving needs of the healthcare sector, emphasizing a shift towards more personalized and versatile heart solutions.</p>

<p>Total Artificial Heart (Dominant) vs. Partial Artificial Heart (Emerging)</p>

<p>The Total Artificial Heart represents a dominant segment within the Artificial Heart Market, offering a complete cardiac replacement for patients whose hearts can no longer function. Its design and technology are rugged and reliable, making it suitable for long-term use. Conversely, the Partial Artificial Heart segment, particularly Ventricular Assist Devices and Biventricular Assist Devices, is considered an emerging solution. These devices offer patients an alternative that can maintain some heart function while addressing less severe heart conditions. The rise of minimally invasive surgeries and a growing aging population are key drivers for the increasing adoption of Partial Artificial Hearts, positioning them favorably for future growth.</p>

By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

<p>In the Artificial Heart Market, the primary end user segment is dominated by hospitals, which account for the largest share due to their comprehensive cardiac care facilities and advanced technology. These institutions are equipped to handle complex surgical procedures, and the necessity for emergency services further cements their position. Following closely are ambulatory surgical centers, which are gaining traction as a cost-effective and patient-friendly option for less critical procedures, enhancing accessibility and convenience for patients seeking artificial heart interventions.</p>

<p>Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)</p>

<p>Hospitals serve as the dominant end user in the Artificial Heart Market, primarily due to their extensive resources, specialized healthcare professionals, and ability to provide a wide range of cardiac interventions. They are typically equipped with advanced imaging and monitoring technologies, facilitating complex surgical procedures that are essential for effective patient care. Conversely, ambulatory surgical centers are emerging as a preferred alternative for many patients, offering minimally invasive procedures with shorter recovery times and lower costs. This growth is attributed to the increasing demand for outpatient services and advancements in medical technology, which make it feasible to perform sophisticated interventions outside traditional hospital settings.</p>

Get more detailed insights about Artificial Heart Market Research Report - Forecast till 2035

Regional Insights

North America : Market Leader in Innovation

North America continues to lead the artificial heart market, holding a significant share of approximately 1290.78 million in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of cardiovascular diseases, and robust investment in medical technology. Regulatory support from agencies like the FDA further catalyzes innovation and market expansion, ensuring that cutting-edge solutions are rapidly adopted to meet patient needs. The competitive landscape in North America is characterized by the presence of major players such as Abbott Laboratories, Medtronic, and Boston Scientific. These companies are at the forefront of technological advancements, offering a range of artificial heart solutions. The U.S. remains the largest market, with a strong focus on research and development, while Canada and Mexico are also emerging as key players in the adoption of artificial heart technologies. The region's commitment to improving patient outcomes drives continuous growth in this sector.

Europe : Emerging Market with Potential

Europe's artificial heart market is valued at 780.93M, reflecting a growing demand for advanced cardiac solutions. Factors such as an aging population, rising healthcare investments, and increasing awareness of heart diseases are driving market growth. Regulatory frameworks in countries like Germany and France are becoming more supportive, facilitating faster approvals for new technologies. Leading countries include Germany, France, and the UK, where major players like Aortech International and CorWave are making significant strides. The competitive landscape is evolving, with a mix of established artificial heart companies and innovative startups. The European market is poised for growth as healthcare systems adapt to new technologies and patient needs.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region, with a market size of 400.0M, is experiencing rapid growth in the artificial heart sector. Key drivers include increasing urbanization, rising disposable incomes, and a growing prevalence of heart diseases. Governments are investing in healthcare infrastructure, which is expected to enhance access to advanced medical technologies. Regulatory bodies are also working to streamline approval processes for new devices. Artificial heart market Japan, China, and India are leading the charge, with a mix of local and international players entering the market. However, the artificial heart transplant cost in India is currently much higher and cannot be afforded by common people. Artificial heart companies such as SynCardia Systems and Jarvik Heart are expanding their presence, contributing to a competitive landscape that is becoming increasingly dynamic and innovative.

Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa (MEA) region is gradually emerging in the artificial heart market, with a market size of approximately 99.22 million projected for 2025. The growth is driven by increasing healthcare investments, rising awareness of cardiovascular diseases, and the establishment of specialized cardiac care facilities. Governments in the region are focusing on improving healthcare infrastructure, which is expected to enhance access to advanced medical technologies, including artificial hearts. Countries like South Africa and the UAE are leading the market, with a growing number of healthcare initiatives aimed at improving patient outcomes. The competitive landscape is evolving, with both local and international players seeking to establish a foothold in this emerging market. As healthcare systems in the MEA region continue to develop, the demand for artificial heart solutions is anticipated to grow significantly, presenting numerous opportunities for market players.

Key Players and Competitive Insights

The Artificial Heart Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cardiovascular diseases, and a growing aging population. Key players such as Abbott Laboratories (US), Medtronic (US), and SynCardia Systems (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott Laboratories (US) focuses on innovation through the development of next-generation heart devices, while Medtronic (US) emphasizes strategic partnerships to expand its product offerings. SynCardia Systems (US) is leveraging its expertise in total artificial hearts to capture a larger market share, indicating a trend towards specialization among leading firms.


The business tactics employed by these companies include localizing manufacturing to reduce cost of artificial heart and optimize supply chains, which is particularly crucial in a moderately fragmented market. This competitive structure allows for a diverse range of products and solutions, fostering innovation while also presenting challenges in terms of market share distribution. The collective influence of these key players shapes the market dynamics, as they vie for leadership through differentiated offerings and strategic collaborations.


In November Medtronic (US) announced a strategic partnership with a leading research institution to develop AI-driven algorithms for optimizing heart pump performance. This collaboration is poised to enhance patient monitoring and device efficiency, reflecting a broader trend towards integrating artificial intelligence in medical devices. Such initiatives may not only improve clinical outcomes but also position Medtronic as a leader in the digital transformation of cardiac care.


In October 2025, Abbott Laboratories (US) launched a new line of minimally invasive heart pumps designed to cater to a wider range of patients, including those with complex medical histories. This initiative underscores Abbott's commitment to expanding access to life-saving technologies, potentially increasing their market share in the artificial heart segment. The focus on minimally invasive solutions aligns with current healthcare trends that prioritize patient comfort and recovery times. The company also emphasizes the reduction of artificial heart cost.


In September 2025, SynCardia Systems (US) received FDA approval for its latest total artificial heart model, which features enhanced biocompatibility and durability. This approval not only validates SynCardia's innovative approach but also positions the company to capture a larger segment of the market as demand for reliable artificial heart solutions continues to grow. The strategic importance of this approval lies in its potential to significantly improve patient quality of life and reduce long-term artificial heart price.


As of December the Artificial Heart Market is witnessing trends that emphasize digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly pivotal, as companies collaborate to enhance their technological capabilities and market reach. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, suggesting a transformative phase for the industry.

Key Companies in the Artificial Heart Market include

Industry Developments

  • Q2 2024: SynCardia Announces FDA Approval for Next-Generation Total Artificial Heart Market SynCardia Systems received FDA approval for its next-generation Total Artificial Heart Market, designed to improve patient outcomes and device durability. The approval marks a significant milestone for the artificial heart company and expands treatment options for patients with end-stage heart failure.
  • Q1 2024: Carmat Receives CE Mark Extension for Aeson Artificial Heart Market Carmat announced that it has received an extension of its CE Mark for the Aeson artificial heart, allowing continued commercial sales and use in European markets. The extension supports ongoing adoption of the device for patients with advanced heart failure.
  • Q2 2024: Carmat Resumes Aeson Artificial Heart Market Production After Manufacturing Suspension Carmat resumed production of its Aeson artificial heart following a temporary suspension due to quality control issues. The artificial heart company implemented corrective actions and received regulatory clearance to restart manufacturing and distribution.
  • Q2 2024: SynCardia Systems Appoints New CEO to Drive Global Expansion SynCardia Systems announced the appointment of a new Chief Executive Officer, aiming to accelerate the company's global expansion and commercialization of its artificial heart technologies.
  • Q1 2024: Carmat Raises €30 Million to Fund Artificial Heart Market Commercialization Carmat completed a €30 million funding round to support the commercialization and scale-up of its Aeson artificial heart in Europe and other markets.
  • Q2 2024: Carmat Signs Distribution Agreement for Aeson Artificial Heart Market in Italy Carmat entered into a distribution agreement with a leading Italian medical device distributor to expand the availability of the Aeson artificial heart in Italy.
  • Q1 2024: FDA Grants Breakthrough Device Designation to BiVACOR Total Artificial Heart Market The FDA granted Breakthrough Device Designation to BiVACOR's Total Artificial Heart Market, recognizing its potential to provide more effective treatment for patients with severe heart failure. This elevates BiVACOR stocks in the market.
  • Q2 2024: BiVACOR stock surges, as BiVACOR Announces First Human Implantation of Total Artificial Heart Market in U.S. Clinical Trial BiVACOR announced the successful first human implantation of its Total Artificial Heart Market as part of a U.S. clinical trial, marking a major milestone in the development of next-generation artificial heart technology.
  • Q2 2024: Carmat Opens New Manufacturing Facility for Aeson Artificial Heart Market Carmat inaugurated a new manufacturing facility dedicated to the production of its Aeson artificial heart, aiming to increase capacity and meet growing demand in Europe.
  • Q1 2024: SynCardia Systems Expands Distribution Network in Asia-Pacific SynCardia Systems announced the expansion of its distribution network in the Asia-Pacific region, partnering with local medical device companies to increase access to its Total Artificial Heart Market.
  • Q2 2024: Carmat Signs Strategic Partnership with Leading U.S. Cardiac Center Carmat entered into a strategic partnership with a major U.S. cardiac center to advance clinical research and adoption of the Aeson artificial heart in the United States.
  • Q1 2024: BiVACOR Secures $22 Million in Series B Funding to Advance Artificial Heart Market Development BiVACOR raised $22 million in Series B funding to accelerate the development and clinical testing of its Total Artificial Heart Market, supporting ongoing trials and regulatory submissions.

Future Outlook

Artificial Heart Market Future Outlook

<p>The Artificial Heart Market is projected to grow at an 8.92% CAGR from 2024 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.</p>

New opportunities lie in:

  • <p>Development of miniaturized artificial hearts for outpatient care Integration of AI for personalized patient monitoring Expansion into emerging markets with tailored financing options</p>

<p>By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic expansion.</p>

Market Segmentation

Artificial Heart Market Type Outlook

  • Total Artificial Heart
  • Partial Artificial Heart
  • Ventricular Assist Device
  • Biventricular Assist Device

Artificial Heart Market End User Outlook

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Home Care Settings

Artificial Heart Market Application Outlook

  • Cardiac Replacement
  • Cardiac Support
  • Heart Valve Replacement
  • Heart Failure Management

Report Scope

MARKET SIZE 2024 2581.55(USD Million)
MARKET SIZE 2025 2841.4(USD Million)
MARKET SIZE 2035 6635.94(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 8.92% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Abbott Laboratories (US), Medtronic (US), Boston Scientific (US), Cleveland Heart (US), Carmen (DE), SynCardia Systems (US), Jarvik Heart (US), Aortech International (GB), Terumo Corporation (JP)
Segments Covered Application, Type, End User
Key Market Opportunities Advancements in biocompatible materials enhance performance and patient outcomes in the Artificial Heart Market.
Key Market Dynamics Technological advancements and regulatory changes drive innovation and competition in the Artificial Heart Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What was the valuation in 2030?

The valuation was USD 4.98 billion.

What is the predicted CAGR for the Artificial Heart Market for the forecast period (2022-2030)?

The predicted CAGR would be 14.3%.

What could slow down market growth?

The high cost of the procedure and regulations regarding the process, along with the higher cost of an artificial heart, can slow down the growth.

Which type to lead the market?

The mechanical heart segment has the chance to record a higher CAGR.

Which region would take charge of the artificial heart market?

The Americas market would dominate the global field.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. EXECUTIVE SUMMARY 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. MARKET INTRODUCTION |
    2. RESEARCH METHODOLOGY 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. MARKET DYNAMICS |
    2. MARKET FACTOR ANALYSIS 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. Healthcare, BY Application (USD Million) |
    2. Healthcare, BY Type (USD Million) |
    3. Healthcare, BY End User (USD Million) |
    4. Healthcare, BY Region (USD Million) 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. Competitive Landscape |
    2. Company Profiles |
    3. Appendix

Artificial Heart Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓